Massivemarkets

ALT

Altimmune, Inc. Common Stock

Nasdaq · usd

$2.08-0.04 (-1.90%)
As of 9:30:14 AM EST on Nov 10, 2026 · 15-minute delayed

Altimmune, Inc. Common Stock (ALT) trades at $2.08 (-1.90%) as of 9:30:14 AM EST on Nov 10, 2026, -18.77% over the past month. Market cap is $412.38M, with 10.4 days to cover in short interest.

Stock performance

How Altimmune, Inc. Common Stock (ALT) stock has performed from one day to one year, with its 52-week range.

-2.82%
-$0.06 over 1D
$2.08$2.10$2.12$2.144:00 AM7:20 AM8:35 AM8:45 AM9:30 AM$2.07
1D
+1.92%
1W
+4.95%
1M
-18.77%
YTD
-41.27%
1Y
-50.47%
52-wk range
$1.91 – $6.44

Key statistics

Today's trading snapshot for ALT: day range, open, previous close, volume and market cap.

Day range
$2.12 – $2.13
Open
$2.12
Prev close
$2.12
Volume
68.65K
Market cap
$412.38M
Shares out
194.52M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Altimmune, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
13302.50
P/B
0.87
P/FCF
—
ROE
-19.4%
ROA
-17.5%
Debt/Equity
0.07
Div yield
0.00%

As of Nov 9, 2026

8-K filings

Material corporate events Altimmune, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Credit facilityOct 29, 2026

    As a result of occurrence and satisfaction of the Tranche 3 Milestone, (i) the Amortization Date and interest-only period has been extended to June 1, 2028, and (ii) pursuant to the Minimum Cash covenant set forth in Section 7.19(a)(i) of the Loan Agreement, the Company shall maintain Qualified Cash in an amount greater than or equal to the outstanding principal amount of the Term Loan Advances multiplied by 60%.

  • Director appointmentOct 27, 2026

    On October 23, 2026, the Board of Directors, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Peter Greenleaf and Alex Howarth as directors of the Board effective November 2, 2026, and approved an increase in its size from nine to eleven directors.

  • Executive officer appointmentSep 29, 2026

    On September 24, 2026, the Board of Directors (the "Board") of Altimmune, Inc. (the "Company") appointed Richard Menziuso as the Company's Vice President, Global Controller and Principal Accounting Officer effective as of September 29, 2026.

  • On July 28, 2026, Altimmune, Inc. (the "Company") issued a press release announcing the positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide 2.4 mg dose, an investigational balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD). The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days per week (HDD) versus placebo, with positive results across important secondary endpoints, including a two-level reduction in the World Health Organization Risk Drinking Level and zero HDDs, both of which are U.S. Food and Drug Administration (FDA) registrational endpoints, as well as a reduction in phosphatidyl ethanol levels. A generally favorable safety and tolerability profile was observed in the trial.

  • Lease agreementJun 16, 2026

    The Company has entered into an office lease agreement for the New Jersey headquarters where the Company will make rent payments of approximately $300,000 annually for the 5-year lease term.

Dividend history and stock splits

Altimmune, Inc. Common Stock's recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 1-for-30Sep 14, 2018
  • 1-for-10May 4, 2017
  • 1-for-50Jul 25, 2007

ALT short interest

How heavily ALT is shorted: shares short, days to cover and average daily volume.

Days to cover
10.4
Short interest
42.23M
Avg volume
4.05M

As of · reported to FINRA twice monthly.

ALT news

The latest news and headlines about Altimmune, Inc. Common Stock (ALT).

Frequently asked questions

What is the Altimmune, Inc. Common Stock (ALT) stock price today?

Altimmune, Inc. Common Stock (ALT) is trading at $2.08 (-1.90% on the day) as of 9:30:14 AM EST on Nov 10, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Altimmune, Inc. Common Stock?

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development…

What is the short interest in ALT?

As of Oct 15, 2026, ALT has 42.23M shares short and 10.4 days to cover.

What exchange is ALT listed on?

Altimmune, Inc. Common Stock (ALT) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of ALT with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ALT analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.